Increased effectiveness of targeted skin cancer screening in the Veterans Affairs population of Northern California

Preventive Medicine

Volumn 36, Issue 2, 2003, Pages 164-171

  Swetter, Susan M ^a,b   Waddell, Barry L ^b   Vazquez, Martin D ^a,b   Khosravi, Vista S ^a,b  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Basal cell; Carcinoma; Carcinoma, Squamous cell; Mass screening; Melanoma

Indexed keywords

ACTINIC KERATOSIS; ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CANCER DIAGNOSIS; CANCER SCREENING; CONTROLLED STUDY; DYSPLASTIC NEVUS; ETHNIC DIFFERENCE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; MELANOMA; PREDICTION; PRIORITY JOURNAL; SKIN CANCER; SOLDIER; SQUAMOUS CELL CARCINOMA; UNITED STATES;

EID: 0347297296     PISSN: 00917435     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-7435(02)00027-0     Document Type: Article

References (54)

1. American Academy of Dermatology, 2001 Melanoma/Skin Cancer Screening Program, Schaumburg, IL, 2002.
2. Swerlick R.A., Chen S. The melanoma epidemic more apparent than real? Mayo Clin Proc. 72:1997;559-564.
3. Edman R.L., Klaus S.N. Is routine screening for melanoma a benign practice? JAMA. 284:2000;883-885.
4. MacKie R.M., McHenry P., Hole D. Accelerated detection with prospective surveillance for cutaneous malignant melanoma in high-risk groups. Lancet. 41:1993;1618-1620.
5. Cristofolini M., Bianchi R., Boi S., DeCarli A., Micciolo R., Cristofolini P., Zumiani G. Effectiveness of the health campaign for the early diagnosis of cutaneous melanoma in Trentino, Italy. J Dermatol Surg Oncol. 19:1993;117-120.
6. Masri G.D., Clark W.H., Guerry D., et al. Screening and surveillance of patients at high risk for malignant melanoma result in detection of earlier disease. J Am Acad Dermatol. 22:1990;1042-1048.
7. Kang S., Barnhill R.L., Mihm M.C. Jr, Fitzpatrick T.B., Sober A.J. Melanoma risk in individuals with clinically atypical nevi. Arch Dermatol. 130:1994;999-1001.
8. Schneider J.S., Moore D.H., Sagebiel R.W. Risk factors for melanoma incidence in prospective followup the importance of atypical (dysplastic) nevi. Arch Dermatol. 130:1994;1002-1007.
9. Rigel D.S., Rivers J.K., Kopf A.W., Friedman R.J., Vinokur A.F., Heilman E.R., Levenstein M. Dysplastic nevi markers for increased risk for melanoma. Cancer. 63:1989;386-389.
10. Weinstock M.A., Goldstein M.G., Dubte C.E., Rhodes A.r, Sober A.J. Basic skin cancer triage for teaching melanoma detection. J Am Acad Dermatol. 34:1996;1063-1066.
11. Weinstock M.A. Early detection of melanoma. JAMA. 284:2000;886-889.
12. Muglia J.J., Pesce K., McDonald C.J. Skin cancer screening a growing need. Surg Oncol Clin N Am. 8:1999;735-745.
13. Rigel D.S. Is the ounce of screening and prevention for skin cancer worth the pound of cure? CA Cancer J Clin. 48:1998;236-238.
14. Brandt T.P. Skin cancer screening. Med Clin North Am. 80:1996;99-114.
15. Screening for skin cancer recommendations and rationale. Am J Prev Med. 20:(3S):2001;44-46.
16. U.S. Preventive Services Task Force: guide to clinical preventive services. 2nd ed. Washington, DC: Office of Disease Prevention and Health Promotion, U.S. Government Printing Office, 1996.
17. McDonald C.J. American Cancer Society perspective on the American College of Preventive Medicine's policy statements on skin cancer prevention and screening. CA Cancer J Clin. 48:1998;232-235.
18. Melanoma detection and symptoms. Available at: http://www3.cancer.org/cancerinfo/. Accessed July 18, 2001.
19. Jonna B.P., Delfino R.J., Newman W.G., Tope W.D. Positive predictive value for presumptive diagnoses of skin cancer and compliance with follow-up among patients attending a community screening program. Prev Med. 27:1998;611-616.
20. Institute of Medicine. Extending medicare coverage for preventive and other services. Washington, DC: National Academy Press, 2000. Screening for skin cancer. p. 38-63.
21. Miller D.R., Geller A., Gilchrest B., Zhang Z., Sober A., Halpern A. Does mass skin cancer screening in the United States substitute for routine melanoma case finding in primary care? Abstracts of the 5th International Conference on Melanoma. Melanoma Res. 11:(Suppl. 1):2001;S148.
22. Koh H.K., Norton L.A., Geller A.C., Sun T., Rigel D.S., Miller D.R., et al. Evaluation of the American Academy of Dermatology's national Skin Cancer Early Detection and Screening Program. J Am Acad Dermatol. 34:1996;971-978.
23. Katris P., Crock J.G., Gray B.N. Research note the Lions Cancer Institute and the Western Australian Society of Plastic Surgeons skin cancer screening programme. Aust NZ J Surg. 66:1996;101-104.
24. Hefland M., Mahon S.M., Eden K.B., Frame P.S., Orleans T.C. Screening for skin cancer. Am J Prev Med. 20:(3S):2001;47-58.
25. Ferrini RL, Perlman M, Hill. American College of Preventive Medicine policy statement: screening for skin cancer. Am J Prev Med 1998;14:80-2.
26. Hill L., Ferrini R.L. Skin cancer prevention and screening summary of the American College of Preventive Medicine's practice policy statements. CA Cancer J Clin. 48:1998;232-235.
27. Katris P., Donovan R.J., Gray B.N. The use of targeted and non-targeted advertising to enrich skin cancer screening samples. Br J Dermatol. 135:1996;268-274.
28. deRooij, Rampen FH, Schouten LJ, Neumann HA. Volunteer melanoma screenings. Follow-up, compliance, and outcome. Dermatol Surg 1997;23:197-201.
29. de Rooij, Rampen FH, Schouten LF, Neumann HA. Skin cancer screening focusing on melanoma yields more selective attendance. Arch Dermatol 1995;131:422-5.
30. Geller A.C., Sober A.J., Zhang Z., Brooks D.R., Miller D.R., Halpern A., Gilchrest B.A. Strategies for improving melanoma education and screening for men ≥ 50 years: findings of the American Academy of Dermatological National Skin Cancer Screening Program. Cancer. 95:2002;1554-1566.
31. Marghoob A.A., Slade J., Salopek T.G., Kopf A.W., Bart R.S., Rigel D.S. Basal cell and squamous cell carcinomas are important risk factors for cutaneous malignant melanoma. Screening implications. Cancer. 75:1995;707-714.
32. VA Palo Alto Health Care System, Strategic Plan, Fact Sheet. Available at http://vapaweb/frontoffice/StrategicPlan/fact_sheet.htm. Accessed September 10, 2002.
33. Bolognia J.L., Berwick M., Fine J.A. Complete follow-up and evaluation of a skin cancer screening in Connecticut. J Am Acad Dermatol. 23:1990;1098-1106.
34. Koh H.K., Caruso A., Gage I., Gellar A.C., Prout M.N., White H., et al. Evaluation of melanoma/skin cancer screening in Massachusetts preliminary results. Cancer. 65:1990;375-379.
35. Field S.I. Melanoma/skin cancer screening in Michigan. J Am Acad Dermatol. 16:1987;578-583.
36. Olsen T.G., Feeser T.A., Conte E.T., Schroeter A.L. Skin cancer screening a local experience. J Am Acad Dermatol. 16:1987;537-541.
37. Schadendorf D., Haas N., Ostmeier H., et al. A campaign to fight malignant melanoma a local experience in Berlin. Eur J Dermatol. 2:1992;532-533.
38. Rampen F.H.J., van Huystee B.E.W.L., Kiemeney L.A.L.M. Melanoma/skin cancer screening clinics experiences in The Netherlands. J Am Acad Dermatol. 25:1991;776-777.
39. Engelberg D., Gallagher R.P., Rivers J.K. Follow-up and evaluation of skin cancer screening in British Columbia. J Am Acad Dermatol. 41:1999;37-42.
40. Scotto J., Kopf, A.W., Urbach F. Non-melanoma skin cancer among Caucasians in four areas of the United States. Cancer. 34:1974;1333-1338.
41. Scotto J, Fears TR, Fraumeni JF Jr. Incidence of nonmelanoma skin cancer in the United States. Washington, DC: U.S. Department of Health and Human Services, 1983. [NIH Publication No. 83-2433].
42. Chuang T.Y., Popescu A.P., Su W.P.D., Chute C.G. Squamous cell carcinoma a population-based incidence study in Rochester, Minnesota. Arch Dermatol. 126:1990;185-188.
43. Chuang T.Y., Popescu A.P., Su W.P.D., Chute C.G. Basal cell carcinoma a population-based incidence study in Rochester, Minnesota. J Am Acad Dermatol. 22:1990;413-417.
44. Serrano H., Scotto J., Shornick G., Fears T.R., Greenberg E.R. Incidence of nonmelanoma skin cancer in New Hampshire and Vermont. J Am Acad Dermatol. 24:1991;574-579.
45. Chuang T.Y., Reizner G.T., Elpern D.J., Stone J.L., Farmer D.R. Squamous cell carcinoma in Kauai, Hawaii. Int J Dermatol. 34:1995;393-397.
46. Gray D.T., Suman V.J., Su D., Clay R.P., Harmsen W.S., Roenigk R.K. Trends in the population-based incidence of squamous cell carcinoma of the skin first diagnosed between 1984 and 1992. Arch Dermatol. 133:1997;735-740.
47. Karagas M.R., Greenberg E.R., Spencer S.K., Stukel T.A., Mott L.A. Increase in incidence rates of basal cell and squamous cell skin cancer in New Hampshire, USA. New Hampshire Skin Cancer Study Group. Int J Cancer. 81:1999;555-559.
48. Harris R.B., Griffith D., Moon T.E. Trends in the incidence of nonmelanoma skin cancers in southeastern Arizona, 1985-1996. J Am Acad Dermatol. 45:2001;528-536.
49. Stern R.S. The mysteries of geographic variability in nonmelanoma skin cancer incidence. Arch Dermatol. 135:1999;843-844.
50. Wolfe J.T. The role of screening in the management of skin cancer. Curr Opinion Oncol. 11:1999;123-128.
51. Gloster H., Brodland D. The epidemiology of skin cancer. Dermatol Surg. 3:1996;217-221.
52. de Rooij M.F., Rampen F.H., Schouten L.J., Neumann H.A. Factors influencing participation among melanoma screening attenders. Acta Derm Venereol. 77:1997;467-470.
53. Bergenmar M., Tornberg S., Brandberg Y. Factors related to non-attendance in a population based melanoma screening program. Psychooncology. 6:1997;218-226.
54. Brandberg Y., Bolund C., Michelson H., Mansson-Brahme E., Ringborg U., Sjoden P.O. Perceived susceptibility to and knowledge of malignant melanoma screening participants vs the general population. Prev Med. 25:1996;170-177.